Article | December 1, 2020

Applying Quality By Design To Pharmaceutical Research And Development

By Shawn Watson, Head of Research and Development

Sterile pharma manufacturing discovery 450x300

The origins of pharmaceutical Quality by Design (QbD) can arguably be traced back to W. Edwards Deming’s book, Out of Crisis, first published in 1982. In the book, Deming introduced his fourteen points of management which have had a significant impact on how organizations pursue intended outcomes. Deming’s third point transformed how we achieve quality; not through a reliance on post-manufacturing testing, but by designing quality into products from the initial stages of development.

The FDA’s guidance concerning QbD began taking shape not long after I began working as a bench chemist, the first role I had in the pharmaceutical industry. QbD has always been a part of my professional life and I hold a strong belief that it begins in the early stages of drug development. It has also been continuously refined by FDA in coordination with industry and my own understanding has been continuously advanced through experience.

The concept of QbD asserts that quality be designed into a drug based on an understanding of the product and the process by which it is developed and manufactured. QbD is often discussed in the context of process development and manufacturing. However, this article focuses on how QbD is applied to research and development (R&D) to drive better results throughout the drug development process.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma

Pharmaceutics International